Top

Published in:

01-09-2008 | Original Paper

Effects of Lactobacillus salivarius 433118 on Intestinal Inflammation, Immunity Status and In vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease

Authors: Linda M. Feighery, Philip Smith, Liam O’Mahony, Padraic G. Fallon, David J. Brayden

Published in: Digestive Diseases and Sciences | Issue 9/2008

Abstract

The probiotic, Lactobacillus salivarius subsp. salivarius 433118 (UCC118), was investigated for its potential to attenuate colitis, modulate immune responses and alter intestinal barrier dysfunction in two different mouse models of inflammatory bowel disease (IBD). Following oral treatment with UCC118, faecal microbial analysis indicated that viable intact bacteria reached the colons of interleukin (IL)-10^−/− mice and dextran sodium sulphate (DSS)-treated mice. Neither prophylactic nor therapeutic UCC118 treatment significantly prevented or attenuated inflammation in either model. In all studies, the probiotic-treated mice had comparable cytokine responses as vehicle-treated animals. Mannitol permeability was increased across colonic mucosae mounted in Ussing chambers from DSS-treated mice, but not in IL-10^−/− mice. However, colonic mucosae from UCC118-treated mice had unchanged transepithelial electrical resistance (TEER) values and mannitol fluxes compared to controls. In two different mouse colitis models examined under a range of histological and functional criteria, the data therefore suggest that this Lactobacillus subsp. has limited potential as a prophylactic or therapeutic treatment for inflammatory bowel disease. While several studies have shown therapeutic activity for this probiotic in mouse models of IBD, our data suggest that there are inter-study variables in formulation, study design, animal models and assessment criteria that may impact on interpretation of probiotic efficacy.

Sheil B, Shanahan F, O’Mahony L (2007) Probiotic effects on inflammatory bowel disease. J Nutr 137:819S–824SPubMed

Rolhion N, Darfeuille-Michaud A (2007) Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis May 2 [Epub ahead of print]

Bartlett JG (2007) Clostridium difficile: old and new observations. J Clin Gastroenterol 41(Suppl 1):S24–S29CrossRef

Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J (2005) Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 11:481–487PubMedCrossRef

Giaffer MH, Holdsworth CD, Duerden BI (1991) The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35:238–243PubMedCrossRef

Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66:5224–5231PubMed

O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRef

Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:1581–1590PubMedCrossRef

Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22:387–394PubMedCrossRef

10.

Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F (2006) Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 4:CD004826PubMed

11.

Macfarlane S, Furrie E, Kennedy A, Cummings JH, Macfarlane GT (2005) Mucosal bacteria in ulcerative colitis. Br J Nutr 93(Suppl 1):S67–S72PubMedCrossRef

12.

Gionchetti P, Rizzello F, Campieri M (2002) Probiotics in gastroenterology. Curr Opin Gastroenterol 18:235–239PubMedCrossRef

13.

Madsen KL, Doyle JS, Jewel LD, Tavernini MM, Fedorak RN (1999) Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107–1114PubMedCrossRef

14.

O’Mahony L, Feeney M, O’Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O’Sullivan G, Shanahan F, Collins JK (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15:1219–1225PubMedCrossRef

15.

McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, Shanahan F (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975–980PubMedCrossRef

16.

Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174:3237–3246PubMed

17.

Llopis M, Antolin M, Guarner F, Salas A, Malagelada JR (2005) Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 54:955–999PubMedCrossRef

18.

Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V (2004) Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats. Scand J Gastroenterol 39:1250–1258PubMedCrossRef

19.

Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Diaz-Ropero MP, Olivares M, Xaus J, Zarzuelo A, Galvez J (2005) Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol 11:5185–5192PubMed

20.

Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailon E, Nieto A, Concha A, Olivares M, Zarzuelo A, Xaus J, Galvez J (2007) A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 97:96–103PubMedCrossRef

21.

Herias MV, Koninkx JF, Vos JG, Huis in’t Veld JH, van Dijk JE (2005) Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J Food Microbiol 103:143–155PubMedCrossRef

22.

Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O’Sullivan GC, Shanahan F, Collins JK (2001) In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73(Suppl 2):386S–392SPubMed

23.

Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CG (2007) Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 104:7617–7721. Epub 2007 Apr 24

24.

May GR, Sutherland LR, Meddings JB (2003) Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology 104:1627–1632

25.

D’Inca R, Di Leo V, Corrao G, Martines D, D’Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC (1999) Intestinal permeability test as a predictor of clinical course in Crohn’s disease. Am J Gastroenterol 94:2956–2960PubMed

26.

Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169:1901–1909PubMedCrossRef

27.

Clark DS (1967) Comparison of pour and surface plate methods for determination of bacterial counts. Can J Microbiol 13:1409–1412PubMedCrossRef

28.

Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274PubMedCrossRef

29.

Melgar S, Karlsson A, Michaelsson E (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288:G1328–G1338PubMedCrossRef

30.

Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, Fallon PG (2007) Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol 178:4557–4566PubMed

31.

Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238–249PubMed

32.

Cuthbert AW (2003) Benzoquinolines and chloride secretion in murine colonic epithelium. Br J Pharmacol 138:1528–1534PubMedCrossRef

33.

Soni J, Baird AW, O’Brien LM, McElroy M, Callanan JJ, Bassett HF, Campion D, Brayden DJ (2006) Rat, ovine and bovine Peyer’s patches mounted in horizontal diffusion chambers display sampling function. J Control Release 115:68–77PubMedCrossRef

34.

Artursson P (1990) Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476–482PubMedCrossRef

35.

Mangan NE, van Rooijen N, McKenzie AN, Fallon PG (2006) Helminth-modified pulmonary immune response protects mice from allergen-induced airway hyperresponsiveness. J Immunol 176:138–147PubMed

36.

Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276:G941–G950PubMed

37.

Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H (1993) Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 105:1643–1650PubMed

38.

Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M (2005) Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140:417–426PubMedCrossRef

39.

Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C (2005) The VSL #3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J Nutr 135:2753–2761PubMed

40.

Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520–528PubMedCrossRef

41.

Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F (2006) Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin Exp Immunol 144:273–280PubMedCrossRef

42.

Madsen KL, Fedorak RN, Tavernini MM, Doyle JS (2002) Normal breast milk limits the development of colitis in IL-10-deficient mice. Inflamm Bowel Dis 8:390–398PubMedCrossRef

43.

Kilara A, Panyam D (2003) Peptides from milk proteins and their properties. Crit Rev Food Sci Nutr 43:607–633PubMedCrossRef

44.

Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR (2001) Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 48:503–507PubMedCrossRef

45.

Byrne FR, Viney JL (2006) Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Devel 9:207–217PubMed

Title: Effects of Lactobacillus salivarius 433118 on Intestinal Inflammation, Immunity Status and In vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease
Authors: Linda M. Feighery
Philip Smith
Liam O’Mahony
Padraic G. Fallon
David J. Brayden
Publication date: 01-09-2008
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 9/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-0157-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of Lactobacillus salivarius 433118 on Intestinal Inflammation, Immunity Status and In vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2008

High Recurrence Rates of Helicobacter pylori Infection Can Be Related to False-Positive Histologies

Surgical Management of Gastroesophageal Reflux Disease in Obesity

Through-the-Scope, Wire-Guided Esophageal Dilation for the Treatment of Food Impaction

The Activity of Class I, II, III, and IV Alcohol Dehydrogenase (ADH) Isoenzymes and Aldehyde Dehydrogenase (ALDH) in Liver Cancer

RDW as an Additional Marker in Inflammatory Bowel Disease/Undifferentiated Colitis

The Epidemiology of Obesity and Gastrointestinal and Other Diseases: An Overview

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page